Lupin receives approval from U.S. FDA for Prasugrel Tablets, USP

Global pharma major Lupin Limited (Lupin) today announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application (ANDA), Prasugrel Tablets USP, 5 mg and 10 mg, a generic equivalent of Effient® Tablets, 5 mg and 10 mg of Cosette Pharmaceuticals, Inc. The product will be manufactured at Lupin's facility in Goa, India.

Prasugrel Tablets USP, 5 mg and 10 mg, (RLD Effient®) had estimated annual sales of USD 18 million in the U.S. (IQVIA MAT September 2022).

Shares of Lupin Limited was last trading in BSE at Rs. 758.85 as compared to the previous close of Rs. 749.20. The total number of shares traded during the day was 26964 in over 1547 trades.

The stock hit an intraday high of Rs. 764.35 and intraday low of 750.00. The net turnover during the day was Rs. 20429996.00.

Source : Equity Bulls

Keywords

Lupin INE326A01037 USFDA ANDA Approval PrasugrelTablets